Image Name - Referrals for Clinicians
(opens in new tab)

How We Work With Healthcare Providers

How We Work With Healthcare Providers

Patients are best served when the all members of the provider/clinical team work together and are fully informed. We value your expertise and welcome the opportunity to support you and your patients.

Submit your referral
Image Name - Referrals for Clinicians

We Work With:

  • Psychiatrists
  • Therapists
  • Psychologists
  • Neurologists
  • Pain Specialists
  • Primary Care Physicians
  • Coaches
  • Social Workers

Treatments for:

  • Depression
  • Anxiety
  • PTSD
  • Migraines & Headaches
  • CRPS & Chronic Pain
  • Immunity & Resilience

Our Services:

  • IV Ketamine
  • Spravato (intranasal Ketamine)
  • Stellate Ganglion Blocks (SGB)
  • IV Nutrients & Vitamins
  • IV NAD+
  • IV Glutathione
  • Ketamine Assisted Psychotherapy (KAP)
  • Life Skills Coaching

Let us help you support your patients!

We pride ourselves on offering our patients a process that is administratively efficient and clinically rigorous while maintining a high level of personalized care and attention.

Step 1: Confirm Your Patient's Interest

The first step is to confirm your patient's openness/interest in infusion therapies such as Ketamine, NAD+, Vitamins, Glutathione, etc. by having a conversation with the differences between Combination Infusion Therapy and conventional approaches to treating anxiety, depression and PTSD.

Step 2: Submit Online Patient Referral Form

If you believe your patient may be a good fit for guided Ketamine treatments, then please tell us a little about them so we may contact them. You can submit a Patient Referral Form here.

Step 3: Review Patient Care Plan With Us

Once we have spoken with your patient and received required documents, we will contact you to confirm/discuss our treatment plan. We value your input and experience and will work closely with you to ensure the best patient care possible.

Step 4: We Provide Ongoing Updates About Treatments and Progress

With your patient's consent, we will share treatment information with you in order to keep you informed of their progress.

Research Papers

Psychedelic Psychiatry’s Brave New World

April 2, 2020

After a legally mandated, decades-long global arrest of research on psychedelic drugs, investigation of psychedelics in the context of psychiatric disorders is yielding exciting results.

NAD+ in Aging: What It Is & Why You Need It

January 28, 2020

Rhonda Patrick explains what NAD+, why it is so important for aging and why it declines with age. She discusses some of the popular NAD+ boosters like nicotinamide riboside and nicotinamide mononucleotide, what animal and human data says and some concluding thoughts.

Study: Ketamine for Chronic Posttraumatic Stress Disorder (PTSD)

January 13, 2020

The authors’ previous proof of- concept randomized controlled trial of single-dose intravenous ketamine infusion in individuals with PTSD showed significant and rapid PTSD symptom reduction 24 hours postinfusion.

NAD+ Boosters: How They Slow Aging

December 10, 2019

Rhonda Patrick explains what NAD+, why it is so important for aging and why it declines with age. She discusses some of the popular NAD+ boosters like nicotinamide riboside and nicotinamide mononucleotide, what animal and human data says and some concluding thoughts.

Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression

November 10, 2019

Elia E. Acevedo-Diaz, Grace W. Cavanaugh, Dede Greenstein, Christoph Kraus, Bashkim Kadriu, Carlos A. Zarate, […]

How effective is ketamine in the management of chronic neuropathic pain?

October 15, 2019

Jack Williams Shteamer, Mayson Augustus Callaway, Parth Patel & Vinita Singh Published Online 15 Oct […]

Resting-state brain functional connectivity in patients with chronic pain who responded to subanesthetic-dose ketamine

September 9, 2019

Yasushi Motoyama, Yoshitetsu Oshiro, Yumiko Takao, Hitoaki Sato, Norihiko Obata, Shinichiro Izuta, Satoshi Mizobuchi & […]

Ketamine Isn’t an Opioid, and it Treats Depression in a Unique Way

July 31, 2019

Ketamine has gotten a bad rap as an opioid when there’s plenty of evidence suggesting it isn’t one, Johns Hopkins experts say. They believe this reputation may hamper patients from getting necessary treatment for the kinds of depression that don’t respond to typical antidepressants.

Scroll to Top